FOLH1 and neoplasm: Finally, [177Lu]Lu-HTK03170 was selected as our lead candidate, and its treatment efficacy was demonstrated by radioligand therapy study in mice bearing PSMA-expressing LNCaP tumor xenografts, and compared with [177Lu]Lu-PSMA-617.